Lymphoma Survivor Mister T to Appear in Rocky VI
Mister T, the actor who played a number of 1980's TV and movie characters recently appeared on the Howard Stern Show. He is a survivor of T cell Non-Hodgkin's lymphoma. He recently said: I still go to the hospital to keep (my cancer) under control. There's no cure but I'm doing well. When I got cancer I found out who my real friends were. Hollywood turned its back on me but Sylvester (Stallone) remained a great buddy.
Mr. T said on Stern he's ready to act in "Rocky VI", reprising the role of Clubber Lang he created in "Rocky III" 23 years ago. This time around Lang will not be fighting Rocky, but instead will be a commentator in the movie. He states he is eager to return to the franchise. "I'm up for anything. We start filming next year. I've been training a bit so I'll be in shape."
Knowing how hard it is to have energy during and after lymphoma treatment, I'm sure it is a testament to T's strength to continue a demanding career. I wish him well, sucka!
More Articles
More Articles
Amazon.com is pleased to have the Lymphoma Information Network in the family of Amazon.com associates. We've agreed to ship items...
The question ought to be what are myelodysplastic syndromes (MDS), since this is a group of similar blood and bone marrow diseases that...
Merkel Cell Carcinoma (MCC) is a very rare and aggressive skin cancer that usually develops when a person is in his or her 70s. It is...
At some point, the Seattle biotech company Cell Therapeutics Inc (CTI) should earn an entry in the Guinness Book of World Records for utter and...
Site Beginnings
This site was started as Lymphoma Resource Page(s) in 1994. The site was designed to collect lymphoma...
Three papers appearing in the journal Blood and pointing towards a regulator-suppressor pill could offer hope to blood cancer...
The US Food and Drug Administration (FDA) has granted a third so-called Breakthrough Therapy Designation for the investigational oral...
The US Food and Drug Administration today has approved an expanded use of Imbruvica (ibrutinib) in patients with...
The U.S. Food and Drug Administration has announced that it has granted "Breakthrough Therapy Designation" for the investigational agent...
According to a new study published in the Proceedings of the National Academy of Sciences, a team from the University of California, San...
Pharmacyclics has announced that the company has submitted a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for...
New research suggests that frontline radioimmunotherapy...
Gilead Sciences has announced results of the company's Phase II study of its investigational compound idelalisib, an oral inhibitor of...
